Chronic Health Conditions in Adult Survivors of Childhood CancerKevin C. Oeffinger, Leslie L. Robison, Cindy L. Schwartz et al.|New England Journal of Medicine|2006Cited by 3.6k
Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing DisciplineWendy Landier, Melissa M. Hudson, Smita Bhatia et al.|Journal of Clinical Oncology|2004Cited by 709
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa Marina, Lisa A. Teot, Sigbjørn Smeland et al.|The Lancet Oncology|2016Cited by 537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan Bielack, Mark L. Bernstein, Sigbjørn Smeland et al.|Journal of Clinical Oncology|2015Cited by 419
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.Richard Görlick, Barry Anderson, Peter M. Anderson et al.|PubMed|2003Cited by 198